22 completed, 12 recruiting, 6 terminated, 3 active not recruiting. 21 Phase 2, 9 Early Phase 1, 7 Phase 1, 5 Phase 4, 4 Phase 3.
Follow fluciclovine F-18: new trials by email Literature Review of fluciclovine F-18 trials Research Report on fluciclovine F-18
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG 18F-Fluciclovine - Glioma, Low-grade Glioma | Early Phase 1 | Recruiting | Children's Hospital of Philadelphia | 30 | 2026-11-29 | 2026-09-22 |
| Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence fluciclovine (18F) - Prostate Cancer | Phase 4 | Recruiting | Blue Earth Diagnostics | 142 | 2026-08-31 | 2026-10-07 |
| Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma Fluciclovine F18 - Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 15 | 2025-05-01 | 2026-09-09 |
| 18F-Fluciclovine PET-MRI in High-grade Glioma 18F-Fluciclovine PET-MRI - Glioma, High Grade Glioma | Early Phase 1 | Recruiting | Children's Hospital of Philadelphia | 30 | 2024-08-07 | 2025-12-04 |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) Biopsy Procedure, Biospecimen Collection, Chest Radiography - Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2024-06-25 | 2026-10-14 |
| Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate - Glioblastoma, IDH-Wildtype | Phase 2 | Recruiting | ECOG-ACRIN Cancer Research Group | 100 | 2024-04-11 | 2026-08-18 |
| 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery 18F fluciclovine - Brain Metastases, Brain Metastases, Adult | Phase 1 | Recruiting | Baptist Health South Florida | 46 | 2024-04-11 | 2026-05-20 |
| 18F-Fluciclovine PET/CT in Multiple Myeloma 18F-fluciclovine injection, 18F-FDG PET/CT - Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-03-25 | 2026-10-16 |
| Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT 18F-fluciclovine, PET/CT - Advanced Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Recruiting | Brigham and Women's Hospital | 30 | 2024-02-01 | 2025-11-05 |
| Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET Fluciclovine PET/CT - Prostate Cancer | Phase 4 | Active not recruiting | OHSU Knight Cancer Institute | 50 | 2023-10-04 | 2026-06-29 |
| Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis 18F-Fluciclovine - Brain Metastases, Brain Cancer | Phase 2 | Recruiting | Baptist Health South Florida | 20 | 2023-01-10 | 2025-12-01 |
| 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy PET imaging with 18F fluciclovine - Grade III or Grade IV Glioma | Phase 3 | Unknown | Nicole Hill | 30 | 2022-08-24 | 2022-10-27 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study Biospecimen Collection, Bone Scan, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | NRG Oncology | 194 | 2022-04-20 | 2026-08-17 |
| Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery 18F fluciclovine - Brain Metastases, Adult, Brain Metastases | Phase 1 | Recruiting | Baptist Health South Florida | 20 | 2022-04-04 | 2026-04-22 |
| 18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants 18F-fluciclovine - Pancreatitis, Graft, Pancreatic Transplant Post-Transplant Dysfunction Rejection | Early Phase 1 | Completed | University of Utah | 4 | 2021-09-16 | 2024-09-03 |
| Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer Computed Tomography, Fluciclovine F18, Gallium Ga 68 Gozetotide - Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma | Phase 1 | Completed | Emory University | 20 | 2021-07-16 | 2025-01-17 |
| A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study) 18F-fluciclovine - Prostate Cancer, Prostate Nodule | Not applicable | Withdrawn | M.D. Anderson Cancer Center | 2021-03-25 | 2024-01-18 | |
| Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases 18F fluciclovine - Brain Metastases | Phase 3 | Completed | Blue Earth Diagnostics | 151 | 2020-10-26 | 2025-08-28 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 804 | 2020-10-08 | 2026-08-19 |
| Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE) 18F fluciclovine - Brain Metastases | Phase 2 | Completed | Blue Earth Diagnostics | 23 | 2020-08-31 | 2025-07-20 |
Showing 20 of 49. Sign in to see all of them.
Prostatic Neoplasms (20) · Brain Neoplasms (10) · Glioblastoma (5) · Glioma (4) · Neoplasms (3) · Disease (2) · Urogenital Diseases (2) · Uterine Cervical Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Lobular (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Lymphoma, Follicular (1) · Multiple Myeloma (1)
Emory University (5) · M.D. Anderson Cancer Center (5) · Blue Earth Diagnostics (4) · Baptist Health South Florida (3) · David M. Schuster, MD (3) · University of Utah (3) · Brigham and Women's Hospital (2) · Children's Hospital of Philadelphia (2) · ECOG-ACRIN Cancer Research Group (2) · National Cancer Institute (NCI) (2) · Abramson Cancer Center at Penn Medicine (1) · Ali Nabavizadeh (1) · Bital Savir-Baruch (1) · Cancer Center of Irvine (1) · Case Comprehensive Cancer Center (1)
United States (47) · Canada (2) · Australia (1) · Italy (1) · New Zealand (1) · Norway (1) · Puerto Rico (1) · United Kingdom (1)
David M Schuster, MD (6) · Jeffrey Yap, PhD (3) · Heather Jacene, MD (2) · Mariam Aboian, MD,PhD (2) · Adrian Harris, Prof (1) · Ali Nabavizadeh, MD (1) · Ashesh B Jani, MD, MSEE (1) · Ashesh Jani, MD, MSEE (1) · Bital Savir-Baruch, M.D (1) · Brian Lewis, MD, MPH, FACP (1) · Bridget F Koontz (1) · Daniel M. Trifiletti, MD (1) · Daniel P Barboriak (1) · David Schuster, MD (1) · Devaki S Surasi (1)
PMID 34081125, PMID 23342303, PMID 27746282, PMID 29685521, PMID 31216198, PMID 31375469, PMID 32347780, PMID 33052718, PMID 33971152, PMID 34795409, PMID 35417762, PMID 36549916, PMID 38421243, PMID 38976035, PMID 42377125
P30CA138292 (2), U10CA180820 (2), P30CA016672 (1), R01CA129356 (1), R01CA169188 (1), R01CA226992 (1), U01CA113913 (1), U10CA180868 (1), U10CA180886 (1)